Pharmacogenomics in Thailand Your guide to cost, top specialists & hospitals

Our partner clinics use accredited laboratories running validated genotyping platforms calibrated against CDC GeT-RM reference materials. The same accreditation and validation standards apply at leading Western pharmacogenomics services. Clinics are staffed by specialists with specific training in pharmacogenomics, not general practitioners interpreting results from a template.

The specialists running these programmes have training in clinical pharmacogenomics, pharmacology, or precision medicine. They understand both the laboratory science and the clinical application: which drug–gene interactions are high-priority, which are theoretical, and how to communicate recommendations effectively to prescribers who may be unfamiliar with pharmacogenomic data.

Confirm that the laboratory is externally accredited and uses validated genotyping arrays. Check that results are interpreted against CPIC/DPWG guidelines specifically, not generic drug-interaction databases. Ask whether a prescriber summary letter is included; without it, your home doctor may not know how to act on the results. And verify that the specialist is available for follow-up communication with your prescriber if needed.

A personalised medication guide showing your metaboliser status for each tested enzyme, mapped against hundreds of medications. Each drug is categorised as standard use, use with caution, or consider alternative, with the specific genotype and guideline reference provided. A clinical summary letter translates the key findings for your prescribing physician.

Patients share the prescriber summary with their home doctor. The report becomes a permanent reference, consulted every time a new medication is considered, a dose is adjusted, or a reaction occurs. Some patients carry a summary card listing their most critical drug–gene interactions for emergency situations. The data never expires because your DNA does not change.

Pharmacogenomic testing in Thailand typically costs between $400 and $650, depending on scope. A targeted 10–15 gene panel sits at the lower end, a comprehensive 200+ medication profile at the higher end. Both include genotyping, analysis, written report, specialist consultation, and prescriber summary.

The total covers initial consultation, sample collection, accredited laboratory genotyping, drug–gene interaction mapping, a personalised medication guide, a specialist results consultation, and a clinical summary letter for your home doctor. A care coordinator supports you throughout.

Scope is the main variable. A targeted panel covering the most impactful pharmacogenes costs less than a comprehensive profile mapping metaboliser status against hundreds of medications. Adding a detailed medication review for patients on multiple current drugs increases the total. Your specialist recommends the scope that matches your needs.

Pricing varies by the complexity and scope of the procedure. Typical ranges at our partner hospitals in Thailand:

• Targeted pharmacogenomics panel (psychiatric medications): $400–$480. Tests genes affecting metabolism of antidepressants, anxiolytics, and mood stabilisers.
• Broad pharmacogenomics panel (multi-drug class): $480–$560. Covers cardiac, pain, oncology, and psychiatric drug metabolism.
• Comprehensive pharmacogenomics with clinical consultation: $560–$650. Full panel plus a specialist review to adjust your current medications.

Exact pricing is confirmed after your consultation and treatment plan are finalised.

Pharmacogenomic testing in Thailand costs 50–70% less than equivalent services in the US ($800–$1,600), Australia (A$700–A$1,400), and UK (£650–£1,200). The savings come from lower clinical costs with no reduction in genotyping accuracy, guideline alignment, or interpretation quality.

Immediately. The test involves a blood draw or cheek swab, nothing that affects travel. Many patients collect their sample during a health screening or clinic visit and fly home the same day. Results are delivered remotely.

No. Genotyping takes two to three weeks. The results consultation and medication review can be conducted via secure video call from anywhere. Staying in Thailand for results is not necessary.

Share the clinical summary with your prescribing physician at home. Every time a new medication is considered, your doctor can check it against your pharmacogenomic profile. The report functions as a permanent prescribing reference: a single test that keeps providing value for the rest of your life.

Yes. Clinical trials have shown that pharmacogenomic-guided prescribing reduces adverse drug reactions compared to standard care. CPIC and DPWG maintain continuously updated, peer-reviewed prescribing guidelines for dozens of drug–gene pairs. The evidence base is robust and growing, which is why major health systems including public health systems are integrating pharmacogenomics into routine care.

Your report is formatted with clinician-friendly language and references established CPIC/DPWG guidelines. It includes a clinical summary letter specifically for prescribers. Most physicians are familiar with pharmacogenomics or can easily interpret the actionable recommendations. Your Thai specialist is available for a collegial discussion with your home doctor if additional context is needed.

If your genotype indicates that a current medication may need dose adjustment or substitution, the recommendation is communicated through the prescriber summary, never implemented without your doctor's involvement. Your pharmacogenomics specialist prioritises the most clinically significant interactions and presents them with supporting evidence so your prescriber can make informed decisions.

No. Most results simply guide future prescribing and can wait for your next routine appointment. A small number are time-sensitive: if you are already taking a high-risk drug that your genotype flags, for example a CYP2C19 poor metaboliser on clopidogrel or a DPYD variant relevant to fluoropyrimidine chemotherapy, your specialist marks it as priority and you should contact your prescriber promptly, the same day where the drug is already in use. Your results consultation states plainly which findings are urgent and which are reference for later.

Genotyping at accredited laboratories is highly accurate and validated against CDC GeT-RM reference materials. The one genuine limitation is gene complexity. CYP2D6 in particular has many star alleles and structural variants, including gene deletions and duplications, that a small percentage of results cannot resolve with full certainty. Reputable laboratories flag these as indeterminate rather than forcing a classification, and confirmatory or repeat testing can be arranged where a result matters clinically.

Some findings are harder to receive, such as learning that a treatment you were counting on is likely ineffective for your genotype, or that a metaboliser status carries implications for blood relatives who may share it. These are prescribing-relevant facts rather than diagnoses of disease, but your specialist talks them through at your results consultation so you understand what they do and do not mean before deciding whether to share them with family.

One to two days is sufficient. Sample collection and initial consultation are completed in a single 30-minute visit. Results are delivered remotely two to three weeks later. Many patients combine pharmacogenomic testing with DNA testing, health screening, or other genetic assessments during the same trip.

Your programme fee covers consultation, sample collection, accredited laboratory genotyping, drug–gene interaction analysis, personalised medication guide, specialist results consultation, prescriber summary letter, and a dedicated care coordinator. No special preparation is required.

Pharmacogenomic testing pairs efficiently with DNA testing and genetic risk assessment. Collecting samples for multiple tests during a single visit saves time and cost. Your coordinator schedules everything into a streamlined programme.